Duration of therapy

OTHER2 trials

Sponsors

Hospital Moinhos de Vento, Methodist Health System

Conditions

Acinetobacter InfectionsBacteremiaBloodstream InfectionCarbapenem Resistant Bacterial InfectionCarbapenem-Resistant Enterobacteriaceae InfectionGram-Negative Bacterial InfectionsHumanMRSA

Unknown Phase

Seven Versus 14 Days of Antibiotic Therapy for Multidrug-resistant Gram-negative Bacilli Infections

TerminatedNCT05210387

Hospital Moinhos de VentoAcinetobacter Infections, Bacteremia, Bloodstream Infection +7

Start: 2022-01-27End: 2023-12-31Updated: 2024-03-06

To Evaluate the Impact of MRSA Nasal Screen Implementation.

CompletedNCT07748143

Methodist Health SystemMRSA

Start: 2019-10-01End: 2026-06-10Updated: 2026-08-05

Related Papers

Seven versus 14 days of antimicrobial therapy for severe multidrug-resistant Gram-negative bacterial infections in intensive care unit patients (OPTIMISE): a randomised, open-label, non-inferiority clinical trial.

2024-12-182 citations

A Randomized, Open-Label, Non-inferiority Clinical Trial Assessing 7 Versus 14 Days of Antimicrobial Therapy for Severe Multidrug-Resistant Gram-Negative Bacterial Infections: The OPTIMISE Trial Protocol.

2023-12-161 citations